Crytalline forms of a pyrazolo [3, 4-c ] pyridine factor Xa inhibitor

Details for Australian Patent Application No. 2005289599 (hide)

Owner Bristol-Myers Squibb Company

Inventors Malley, Mary F.; Chen, Bang-Chi; Yin, Xiaotian S.; Murphy, Denette K.; McGeorge, Gary; Zhang, Huiping; Fabian, Steven R.; Gupta, Jasmine M.; Dimarco, John D.; Gleeson, Margaret M.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2005289599

PCT Pub. Number WO2006/036927

Priority 11/235,519 26.09.05 US; 60/613,656 28.09.04 US

Filing date 27 September 2005

Wipo publication date 6 April 2006

International Classifications

C07D 471/04 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/437 (2006.01)

A61P 7/02 (2006.01) Drugs for disorders of the blood or the extracellular fluid

Event Publications

19 April 2007 PCT application entered the National Phase

  PCT publication WO2006/036927 Priority application(s): WO2006/036927

8 October 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005289610-Self-constrained segmented stents and methods for their deployment

2005289598-Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones